Pharma R&D Trends - Resources PharmaLinkage

The pharmaceutical industry stands at a crossroads in 2025. Will biotech finally overtake traditional drug development? Can China’s meteoric rise in pharma R&D continue? And with global M&A activity heating up, which companies will emerge as the next powerhouses of innovation?

Our Pharma R&D Review dives deep into these questions, unpacking the trends shaping the future of drug discovery. From the surge in biotech-based drugs to the shifting dynamics of R&D hotspots, we analyze where the industry is headed—and what companies must do to stay ahead. The stakes have never been higher. Let’s explore the road ahead.

Setting the Stage for Innovation in 2025

Pharmaceutical R&D is the engine of medical innovation, with spending set to exceed $260 billion in 2025. AI-driven drug discovery, gene therapies, and personalized medicine are driving breakthroughs, yet access remains uneven. While the global pharmaceutical market is worth $1.6 trillion, cutting-edge treatments remain concentrated in wealthier regions, limiting healthcare equity.

Oncology dominates R&D, accounting for over one-third of drug pipelines, while metabolic disorders like obesity and diabetes are gaining momentum. The success of mRNA vaccines has accelerated responses to emerging health threats, shaping trends in antimicrobial resistance and neurodegenerative diseases. As we explore 2025’s R&D landscape, scientific progress, market dynamics, and regulation will determine not just new treatments but who benefits from them.

Accelerate Innovation with the Perfect R&D Collaboration

Start Now

Mapping the Pharma R&D Pipeline in 2025

The pharmaceutical R&D pipeline has expanded again, with 23,875 drugs in development—a 4.6% increase over 2024. Though lower than last year’s 7.2% growth, this steady rise highlights the industry’s commitment to innovation. The pipeline spans all stages, from preclinical research to regulatory approval, including launched drugs undergoing expansion. Despite disruptions in data collection, 4,546 new drugs were added in 2024, reflecting sustained momentum. However, this marks the slowest growth rate of the decade, raising questions about whether the industry is entering a phase of strategic recalibration.

Oncology continues to dominate, making up 38.8% of newly identified R&D drugs, followed by neurology at 13.8%. Rare diseases remain a focus, with 20% of new drugs targeting them. Novartis led with 37 new candidates, while China’s Jiangsu Hengrui Pharmaceuticals followed closely with 36, signaling China’s rising influence. With 1,683 new drugs from the US and 1,495 from China, the innovation race is tightening.

Pipeline Progress: Where Drugs Stand in 2025

The 2025 R&D pipeline sees varied growth across different phases. Preclinical drugs increased by just 1.8% (compared to 5.5% in 2024), signaling a slowdown in early-stage discovery. Clinical-phase drugs, however, show more movement: Phase I grew by 6.8% (down from 13.5% last year), Phase II by 6.3% (7.8% in 2024), and Phase III by 8.8%, a sharp rise from last year’s 1.6%. These numbers reflect the natural bottlenecks of drug development—while many drugs enter early trials, fewer advance due to attrition. Drugs accumulate in Phase II, where trials take longer, making it appear nearly as crowded as Phase I.

With more drugs progressing to Phase III, the industry could see a surge in market launches. Yet, drug development remains a high-risk game—some bets pay off, while others vanish without a trace. As always, pharma leaders will be hoping this year’s pipeline delivers blockbuster successes rather than fashion faux pas.

Pharma’s Power Players: Who’s Leading the Pipeline?

The top 25 pharma giants continue to dominate the R&D pipeline, but with a revised calculation this year—now including drugs from their subsidiaries—the numbers appear slightly inflated. Despite this, the true trend remains clear: pipeline expansion among these firms is largely aligned with the industry-wide 4% growth. Pfizer reclaims the top spot after briefly conceding it to Roche last year, while Novartis closes in at No. 3. The biggest mover is Sanofi, leaping to No. 5, while Jiangsu Hengrui Pharmaceuticals—China’s breakout star—drops out of the top 10 but remains No. 1 in self-originated products. Chinese influence grows, with CSPC Pharmaceutical climbing and BeOne Medicines (formerly BeiGene) debuting at No. 25.

Beyond the industry titans, small firms are thriving. There are now 997 companies with two drugs in their pipeline (up from 931), and 2,638 firms with just one molecule (up from 2,249). These boutique players now contribute 19.4% of the total pipeline, proving that innovation isn’t just for the big names—it’s also being stitched together in pharma’s equivalent of startup fashion studios.

Pharma’s Power Players: Who’s Leading the Pipeline?

The Evolving Geography of Pharma R&D

Pharmaceutical R&D has become increasingly global, with China’s rapid rise reshaping the landscape. Just 20 years ago, China’s industry focused on generics and traditional medicines, with little emphasis on novel drug development. Fast forward to 2025, and 17% of all pharma R&D firms are now based there, up from 16% last year. While the US remains the leader with 39%, China has firmly secured second place, well ahead of South Korea (413 firms) and the UK. This shift reflects China’s strong investment in innovation and its growing importance in global drug development.

Looking at where R&D is actually happening, the US still dominates with 48.0% of active drug development, though this is slightly down from 49.1% in 2024. Meanwhile, China’s share has risen from 26.7% to 29.5%, as more Western companies seek approvals in the Chinese market. South Korea maintains its No. 3 position, keeping the UK at No. 4. With R&D reported in 162 countries, the global footprint of drug development continues to expand.

Biotech’s Comeback: On the Verge of Dominance

After last year’s data hinted at a slowdown, this year’s figures confirm that biotech’s rise is back on track. As shown in Figure 27, biotech-based drugs now account for 49.8% of the pipeline, edging closer to overtaking traditional small molecules. The apparent plateau in growth last year seems to have been a temporary pause rather than a true shift in trajectory. A change in how immunoconjugates are classified—now counted as both chemical and biological—has contributed to the increase, but even without this adjustment, biotech’s dominance appears inevitable.

Biotech’s Comeback: On the Verge of Dominance

Navigating 2025: The Road Ahead for Pharma R&D

With a third of 2025 already behind us, the pharmaceutical industry continues to chart a steady course, driven by innovation and strategic growth. Biotech-based drugs are gaining momentum, new active substances are entering the market at a strong pace, and drug development is expanding its reach to more protein targets than ever. While the Phase II to Phase III transition remains a hurdle, this year has shown promising signs of progress. Mergers and acquisitions are also picking up, supported by improving economic conditions and big pharma’s need to replenish pipelines. A shifting regulatory landscape could further accelerate deal-making and innovation.

Looking ahead, collaboration will be the defining factor for success in pharma R&D. With complex new modalities like gene and cell therapies requiring specialized expertise, strategic partnerships between big pharma, biotech startups, and academia will be critical. Companies that build the right alliances will unlock new breakthroughs, securing a competitive edge and ensuring long-term growth.

Industry News

Insightful and opinionated analysis of the latest pharma news about developments shaping the pharmaceutical industry landscape that help you navigate the dynamic world of pharmaceutical industry trends and stay informed about the forces driving change.